MedPath

SIGKNOW BIOMEDICAL CO., LTD.

🇹🇼Taiwan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

2 Phases

Phase 4:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (50.0%)
Phase 4
1 (50.0%)

An Open-label Study of EZYPRO® in Atrial Fibrillation Detection on ESUS Patients

Phase 4
Conditions
Embolic Stroke of Undetermined Source
Atrial Fibrillation
First Posted Date
2021-10-22
Last Posted Date
2022-05-10
Lead Sponsor
Sigknow Biomedical Co., Ltd.
Target Recruit Count
500
Registration Number
NCT05089435
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

Comparison of 24-hour Holter Monitoring Versus 14-day Continuous ECG Patch Monitoring EZYPRO

Not Applicable
Conditions
Atrial Fibrillation
Arrhythmias, Cardiac
First Posted Date
2018-07-27
Last Posted Date
2018-07-27
Lead Sponsor
Sigknow Biomedical Co., Ltd.
Target Recruit Count
150
Registration Number
NCT03602742
Locations
🇨🇳

Taipei Veterans General Hospital, Taiwan, Taipei, Taiwan

🇨🇳

Chang Gung Medical Foundation, Linkou, Taoyuan, Taiwan

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.